Positron emission tomography imaging of oestrogen receptor-expression in endometrial stromal sarcoma supports oestrogen receptor-targeted therapy: case report and review of the literaturevan Kruchten, M., Hospers, G. A. P., Glaudemans, A. W. J. M., Hollema, H., Arts, H. J. G. & Reyners, A. K. L., Dec-2013, In : European Journal of Cancer. 49, 18, p. 3850-3855 6 p.
Research output: Contribution to journal › Review article › Academic › peer-review
Although the majority of endometrial stromal sarcomas (ESSs) express oestrogen receptor (ER), data on the efficacy of ER-targeted therapies are scarce. Using PubMed search engine we identified nine case reports and small series in a total of 25 patients reporting on the efficacy of palliative ER-targeted therapies. Literature supports the efficacy of aromatase inhibitors after the failure of progestins, but not of the partial ER-antagonist tamoxifen. Fulvestrant is a pure ER-antagonist with a distinct mechanism, of which efficacy has not yet been reported in ESS. We present a patient that underwent positron emission tomography and computed tomography (PET/CT) of ER-expression with the tracer (18)F-fluoroestradiol (FES). High levels of ER-expression provided a rationale for fulvestrant therapy. FES-PET/CT was repeated after 6 months and indicated a strong decrease in tumour FES-uptake, and 15% reduction in tumour diameters according to Response Evaluation Criteria in Solid Tumours (RECIST) criteria.
|Number of pages||6|
|Journal||European Journal of Cancer|
|Publication status||Published - Dec-2013|
- Adult, Endometrial Neoplasms/diagnostic imaging, Estradiol/analogs & derivatives, Estrogen Antagonists/therapeutic use, Female, Fulvestrant, Humans, Positron-Emission Tomography/methods, Receptors, Estrogen/antagonists & inhibitors, Sarcoma, Endometrial Stromal/diagnostic imaging, Time Factors, Treatment Outcome, Tumor Burden/drug effects